Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines

Auris Nasus Larynx

Volumn 38, Issue 5, 2011, Pages 589-599

  Sakakibara, Atsuko ^a   Tsukuda, Mamoru ^a   Kondo, Norio ^a   Ishiguro, Yukari ^a   Kimura, Machiko ^a   Fujita, Kyoko ^a   Takahashi, Hideaki ^a   Matsuda, Hideki ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cell cycle; Chemotherapy; Doubling time; E1A; Head and neck squamous cell carcinoma; Telomelysin (OBP 301); Virotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; E1A PROTEIN; MYC PROTEIN; OBP 301; PACLITAXEL; STREPTOLYSIN O; TELOMELYSIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ADENOVIRUS INFECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; VIRUS INFECTIVITY;

ADENOVIRIDAE INFECTIONS; ADENOVIRUS E1A PROTEINS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BACTERIAL PROTEINS; CARCINOMA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASMS, SQUAMOUS CELL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PACLITAXEL; RECEPTORS, VIRUS; RNA, MESSENGER; S PHASE; STREPTOLYSINS; TELOMERASE;

EID: 79954582131     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2011.01.018     Document Type: Article

References (44)

1. Aigner S., Postberg J., Lipps H.J., Cech T.R. The Euplotes La motif protein p43 has properties of a telomerase-specific subunit. Biochemistry 2003, 42:5736-5747.
2. Forastiere A.A., Goepfert H., Maor M., Pajak T.F., Weber R., Morrison W., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349:2091-2098.
3. Kirn D., Martuza R.L., Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001, 7:781-787.
4. Hawkins L.K., Lemoine N.R., Kirn D. Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol 2002, 3:17-26.
5. Blackburn E.H. Structure and function of telomeres. Nature 1991, 350:569-573.
6. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
7. Shay J.W., Wright W.E. Telomerase activity in human cancer. Curr Opin Oncol 1996, 8:66-71.
8. Nakayama J., Tahara H., Tahara E., Saito M., Ito K., Nakamura H., et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998, 18:65-68.
9. Kawashima T., Kagawa S., Kobayashi N., Shirakiya Y., Umeoka T., Teraishi F., et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004, 10:285-292.
10. Taki M., Kagawa S., Nishizaki M., Mizuguchi H., Hayakawa T., Kyo S., et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 2005, 24:3130-3140.
11. Hashimoto Y., Watanabe Y., Shirakiya Y., Uno F., Kagawa S., Kawamura H., et al. Establishment of biological and pharmacokinetic assays of telomerase-specific replication-selective adenovirus. Cancer Sci 2008, 99:385-390.
12. Kyo S., Takakura M., Fujiwara T., Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 2008, 99:1528-1538.
13. Fujita K., Kimura M., Kondo N., Sakakibara A., Sano D., Ishiguro Y., et al. Anti-tumor effects of telomelysin for head and neck squamous cell carcinoma. Oncol Rep 2008, 20:1363-1368.
14. Kondo N., Tsukuda M., Kimura M., Fujita K., Sakakibara A., Takahashi H., et al. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma. Oncol Rep 2010, 23:355-363.
15. Kooby D.A., Carew J.F., Halterman M.W., Mack J.E., Bertino J.R., Blumgart L.H., et al. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999, 13:1325-1334.
16. Donaldson K.L., Goolsby G.L., Wahl A.F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 1994, 57:847-855.
17. Horwitz S.B. Mechanism of action of taxol. Trends Pharmacol Sci 1992, 13:134-136.
18. Fujiwara T., Tanaka N. Telomerase-specific oncolytic virotherapy for human cancer with the hTERT promoter. Uirusu 2008, 58:11-18.
19. Doloff J.C., Waxman D.J. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. Cancer Gene Ther 2011, 18:153-166.
20. Fernandes M.S., Gomes E.M., Butcher L.D., Hernandez-Alcoceba R., Chang D., Kansopon J., et al. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clin Cancer Res 2009, 15:4847-4856.
21. Sagawa T., Yamada Y., Takahashi M., Sato Y., Kobune M., Takimoto R., et al. Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice. Hepatology 2008, 48:828-840.
22. Kim M., Zinn K.R., Barnett B.G., Sumerel L.A., Krasnykh V., Curiel D.T., et al. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells. Eur J Cancer 2002, 38:1917-1926.
23. Watanabe T., Hioki M., Fujiwara T., Nishizaki M., Kagawa S., Taki M., et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 2006, 312:256-265.
24. Dechecchi M.C., Melotti P., Bonizzato A., Santacatterina M., Chilosi M., Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001, 75:8772-8780.
25. Hong S.S., Karayan L., Tournier J., Curiel D.T., Boulanger P.A. Adenovirus type 5 fiber knob binds to MHC class I alpha2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO J 1997, 16:2294-2306.
26. Nakajima O., Matsunaga A., Ichimaru D., Urata Y., Fujiwara T., Kawakami K. Telomerase-specific virotherapy in an animal model of human head and neck cancer. Mol Cancer Ther 2009, 8:171-177.
27. Kurihara Y., Watanabe Y., Onimatsu H., Kojima T., Shirota T., Hatori M., et al. Telomerase-specific virotheranostics for human head and neck cancer. Clin Cancer Res 2009, 15:2335-2343.
28. Cong Y.S., Wen J., Bacchetti S. The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 1999, 8:137-142.
29. Wang J., Xie L.Y., Allan S., Beach D., Hannon G.J. Myc activates telomerase. Genes Dev 1998, 12:1769-1774.
30. Wu K.J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999, 21:220-224.
31. Greenberg R.A., O'Hagan R.C., Deng H., Xiao Q., Hann S.R., Adams R.R., et al. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 1999, 18:1219-1226.
32. Kyo S., Takakura M., Taira T., Kanaya T., Itoh H., Yutsudo M., et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000, 28:669-677.
33. Hu X., Yu N., Fu L., Su W., Huang G., Wu Y., et al. Downregulation of human telomerase reverse transcriptase through anti-C-myc siRNA in human colon cancer Colo 320 cells. Nucleos Nucleot Nucl Acids 2009, 28:1-11.
34. Herbst R.S., Pelletier M., Boczko E.M., Babiss L.E. The state of cellular differentiation determines the activity of the adenovirus E1A enhancer element: evidence for negative regulation of enhancer function. J Virol 1990, 64:161-172.
35. Bruder J.T., Hearing P. Cooperative binding of EF-1A to the E1A enhancer region mediates synergistic effects on E1A transcription during adenovirus infection. J Virol 1991, 65:5084-5087.
36. Flak M.B., Connell C.M., Chelala C., Archibald K., Salako M.A., Pirlo K.J., et al. p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Mol Cancer 2010, 9:175.
37. Deng W.G., Jayachandran G., Wu G., Xu K., Roth J.A., Ji L. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells. J Biol Chem 2007, 282:26460-26470.
38. Wang H.G., Draetta G., Moran E. E1A induces phosphorylation of the retinoblastoma protein independently of direct physical association between the E1A and retinoblastoma products. Mol Cell Biol 1991, 11:4253-4265.
39. Hollyoake M., Stuhler A., Farrell P., Gordon J., Sinclair A. The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. Cancer Res 1995, 55:4784-4787.
40. Morozov A., Shiyanov P., Barr E., Leiden J.M., Raychaudhuri P. Accumulation of human papillomavirus type 16 E7 protein bypasses G1 arrest induced by serum deprivation and by the cell cycle inhibitor p21. J Virol 1997, 71:3451-3457.
41. Ingemarsdotter C.K., Baird S.K., Connell C.M., Oberg D., Hallden G., McNeish I.A. Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene 2010, 29:6051-6063.
42. Takakura M., Nakamura M., Kyo S., Hashimoto M., Mori N., Ikoma T., et al. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther 2010, 17:11-19.
43. Brito J.L., Brown N., Morgan G.J. Transfection of siRNAs in multiple myeloma cell lines. Methods Mol Biol 2010, 623:299-309.
44. Milosavljevic N., Duranton C., Djerbi N., Puech P.H., Gounon P., Lagadic-Gossmann D., et al. Nongenomic effects of cisplatin: acute inhibition of mechanosensitive transporters and channels without actin remodeling. Cancer Res 2010, 70:7514-7522.